Organ inflammation in porcine Escherichia coli sepsis is markedly attenuated by combined inhibition of C5 and CD14

Immunobiology. 2015 Aug;220(8):999-1005. doi: 10.1016/j.imbio.2015.04.002. Epub 2015 Apr 27.

Abstract

Sepsis is an infection-induced systemic inflammatory syndrome, potentially causing organ failure. We previously showed attenuating effects on inflammation, thrombogenicity and haemodynamics by inhibiting the Toll-like receptor co-factor CD14 and complement factor C5 in a porcine Escherichia coli-induced sepsis model. The present study explored the effect on organ inflammation in these pigs. Tissue samples were examined from the combined treatment group (n = 8), the positive (n = 8) and negative (n = 6) control groups after 4h of sepsis. Inflammatory biomarkers were measured using ELISA, multiplex and qPCR analysis. Combined inhibition of C5 and CD14 markedly attenuated IL-1β by 31-66% (P < 0.05) and IL-6 by 54-96% (P < 0.01) in liver, kidney, lung and spleen; IL-8 by 65-100% in kidney, lung, spleen, and heart (P < 0.05) and MCP-1 by 46-69% in liver, kidney, spleen and heart (P < 0.05). Combined inhibition significantly attenuated tissue factor mRNA upregulation in spleen (P < 0.05) and IP-10 mRNA upregulation in four out of five organs. Finally, C5aR mRNA downregulation was prevented in heart and kidney (P < 0.05). Combined inhibition of C5 and CD14 thus markedly attenuated inflammatory responses in all organs examined. The anti-inflammatory effects observed in lung and heart may explain the delayed haemodynamic disturbances observed in septic pigs receiving combined inhibition of C5 and CD14.

Keywords: CD14; Complement; Inflammation; Porcine; Sepsis; Tissue.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cells, Cultured
  • Chemokine CCL2 / metabolism
  • Complement C5 / antagonists & inhibitors*
  • Disease Models, Animal
  • Escherichia coli / immunology*
  • Escherichia coli Infections / immunology
  • Escherichia coli Infections / therapy*
  • Gene Expression Regulation / drug effects
  • Humans
  • Inflammation / immunology
  • Inflammation / therapy
  • Interleukin-1beta / metabolism
  • Interleukin-6 / metabolism
  • Lipopolysaccharide Receptors / immunology*
  • Multiple Organ Failure / microbiology
  • Multiple Organ Failure / therapy*
  • Receptor, Anaphylatoxin C5a / genetics
  • Receptor, Anaphylatoxin C5a / metabolism
  • Sepsis / immunology
  • Sepsis / therapy*
  • Swine

Substances

  • Chemokine CCL2
  • Complement C5
  • Interleukin-1beta
  • Interleukin-6
  • Lipopolysaccharide Receptors
  • Receptor, Anaphylatoxin C5a